City aids 2 firms' relocationTwo companies will...

City aids 2 firms' relocation

Two companies will get city funds to assist with relocation and expansion in Baltimore, Baltimore Development Corp., the city's economic growth agency, announced yesterday.


Osiris Therapeutics Inc., which is preparing to move its biotechnology operations to Baltimore from Cleveland, will receive a $200,000 city investment in the firm's preferred stock, as part of an investment plan approved by the city Board of Estimates.

The investment is part of an assistance package that also includes a $3 million insured bond issue, a state investment of $250,000 in the firm's preferred stock, a state contribution of $150,000 to help renovate space in the SAGA building at Fells Point and a city cash reserve of $250,000 to support the bond issue.


Maran Inc., a local firm that prints and laminates plastic products ranging from bank cards to computer templates, will receive a $100,000 loan from the BDC to help it renovate and expand a building at 3521 E. Federal St. and move there from its existing quarters on North Eutaw Street.

Apple alleges Microsoft threats

The antitrust case against Microsoft Corp. escalated yesterday as allegations surfaced from Apple Computer Inc. that Microsoft executives threatened to withhold software from Apple unless it dropped lawsuits and quit developing a competing product.

The Cupertino, Calif., company said in a letter to U.S. District Judge Stanley Sporkin that Microsoft's Chairman Bill Gates personally issued a "thinly veiled threat" last month to discontinue selling Microsoft's software programs for Apple's Macintosh line of computers if Apple did not drop plans to develop its own version of a software technology.

Apple's letter was delivered to Judge Sporkin on Feb. 13, the day before the judge issued his 45-page ruling rejecting the rTC Justice Department's proposed antitrust settlement with Microsoft.

Oncologix, 2 Texas firms merging

Oncologix Inc. of Gaithersburg announced yesterday that it will merge with Argus Pharmaceuticals Inc. and Triplex Pharmaceutical Corp., both of Woodlands, Texas. The companies' operations will be consolidated in Texas.

Under the terms of the agreement, subject to shareholder approval, Oncologix shareholders will exchange all stock, options and warrants for a series of warrants to purchase common stock in the new company.


USAir to sell 11 airliners

USAir Group Inc. said yesterday that it agreed to sell 11 Boeing 737-300 aircraft to General Electric Capital Corp. for an undisclosed amount.

USAir Chairman Seth E. Schofield said the sale is part of the company's plan to cut expenses by at least $1 billion a year.